Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential

MLA

Muhammad Mujammami, et al. “Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential.” Pharmaceuticals, vol. 16, no. 12, Dec. 2023, p. 1717. EBSCOhost, https://doi.org/10.3390/ph16121717.

APA

Muhammad Mujammami, Shereen M. Aleidi, Adriana Zardini Buzatto, Awad Alshahrani, Reem H. AlMalki, Hicham Benabdelkamel, Mohammed Al Dubayee, Liang Li, Ahmad Aljada, & Anas M. Abdel Rahman. (2023). Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential. Pharmaceuticals, 16(12), 1717. https://doi.org/10.3390/ph16121717

Chicago

Muhammad Mujammami, Shereen M. Aleidi, Adriana Zardini Buzatto, Awad Alshahrani, Reem H. AlMalki, Hicham Benabdelkamel, Mohammed Al Dubayee, Liang Li, Ahmad Aljada, and Anas M. Abdel Rahman. 2023. “Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential.” Pharmaceuticals 16 (12): 1717. doi:10.3390/ph16121717.